Key Highlights: Implications: Zintrodiazine’s Phase III go‑ahead positions Zydus as a front‑line Indian innovator in a space long dominated by global public–privat...
Key Highlights: Implications: Rubicon is using the Arinna deal to buy its way into India’s fast‑growing CNS and neuro‑psychiatry market with an immediately revenue‑accretive, chr...
Key Highlights: Implications: Aragen is using ChemiSHE to make gender diversity a visible part of its R&D operating model: an all‑women chemistry synthesis lab in ...
Key Highlights: Implications: AstraZeneca India is partnering with Telangana to embed Qure.ai’s chest X‑ray AI into routine workflows at about 20 public facilities, turning basic radiography into a lu...
Key Highlights: Implications: Emcure is effectively repositioning Poviztra as a mass‑market GLP‑1 for obesity in India, using a steep 55% entry‑dose cut (now ₹3,999/mon...
Key Highlights: Implications: Rusan’s new APOSAN 3 ml multi‑dose pen broadens at‑home rescue options for Indian Parkinson’s patients by adding a dial‑a‑dose, cartridge‑based apom...
Key Highlights: Implications: CORONA Remedies is using the Wokadine acquisition to buy its way into India’s ₹648 crore povidone-iodine market with a #2-ranked, 46‑year-old antise...
Key Highlights: Implications: HRV Pharma is using the Shodhana alliance to turn its AI‑enabled “Virtual API” model into tangible, regulated assets, starting with a pharmaceutical...
Key Highlights: Implications: Wockhardt’s SEC nod for Zaynich marks a major step toward India’s first home-grown, dual‑mechanism anti‑Gram‑negative launched in the carbapenem‑resistan...
Key Highlights: Implications: Biocon is consolidating leadership under Shreehas Tambe to drive its newly integrated biosimilars–generics platform, with a clear focus on...